New BioMedicine Special Event Report
Ariad Pharmaceuticals, Inc. (ARIA) - Data from the Phase II trial of Ridaforolimus for HER2 positive Metastatic Breast Cancer
| Date: | Oct 01, 2009 |
|---|---|
| Format: | |
| Price: | $40.00 |
Abstract
Event-based Healthcare Investment Report for Ariad Pharmaceuticals, Inc. (ARIA) - Data from the Phase II trial of Ridaforolimus for HER2 positive Metastatic Breast Cancer
New BioMedicine Biotech Research Report provides in-depth analysis relating to an upcoming event for a select pipeline drug. The report forecasts the expected event outcome (positive/negative), and discusses the relevant company, the drug candidate, market opportunity, clinical trials results, and competitive landscape.
The Biotech Research Report is unique in its focus on events likely to drive large price movements within narrow timeframes, and because it forecasts event outcomes based on rigorous analysis of clinical results and regulatory factors.
Companies Mentioned in the Report
More Information:
Learn more about New BioMedicine Event Report.